Objectives: To detect chromosomal aberrations in a genome-wide manner with potential value for prognosis in groups of patients with different histopathological grading in clear cell renal carcinoma (ccRCC). Material and Methods: We performed a copy number alteration analysis using the Affymetrix platform and SNP 6.0 mapping arrays with samples from 48 ccRCC-patients. The data analysis was done using 3 different Software Platforms: Affymetrix Genotyping Console (version 4.1.3.840) and 2 open-source packages for validation: PennCNV and PICNIC. Results: Consistent changes were found to divide the tumors into 4 groups: first group showed typical losses on 3p, second group losses on 3p plus gains on 5q, third group gains on chromosome 7 plus losses on chromosome 8; fourth group did not show any major changes. We selected the affected genes with the highest consistency and identified 13 different genes mapping in the SNP 6.0 results and Kyoto Encyclopedia of Genes and Genomes. Remarkable for further consideration were the phosphatidylinositol 3-kinase pathway, BRAF, MET, EGLN1; growth factors, for example, HGF, PGF and TGFB2. Conclusion: A multimodal approach with a well-defined workflow for detecting genomic aberrations by using array technologies and comparing the findings with different comprehensive databases may provide insights into functional tumor processes and help to identify potential new targets for more individualized future treatment.

Keywords:
Renal cell carcinoma, Copy number alterations, Genomic alterations, Prognostic factors, Pathway analysis
1.
Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr: Rising incidence of renal cell cancer in the United States. JAMA 1999; 281: 1628–1631.
2.
Kovacs G, Akhtar M, Beckwith BJ, et al: The Heidelberg classification of renal cell tumors. J Pathol 1997; 183: 131–133.
3.
Gunawan B, Huber W, Holtrup M, et al: Prognostic impacts of cytogenetic findings in clear cell renal cell carcinoma: gain of 5q31-qter predicts a distinct clinical phenotype with favorable prognosis. Cancer Res 2001; 61: 7731–7738.
4.
Höglund M, Gisselsson D, Soller M, Hansen GB, Elfving P, Mitelman F: Dissecting karyotypic patterns in renal cell carcinoma: an analysis of the accumulated cytogenetic data. Cancer Genet Cytogenet 2004; 153: 1–9.
5.
Banks RE, Tirukonda P, Taylor C, et al: Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 2006; 66: 2000–2011.
6.
Higgins JP: Gene array studies in renal neoplasia. Sci World J 2006; 6: 502–511.
7.
Speicher MR, Carter NP: The new cytogenetics: blurring the boundaries with molecular biology. Nat Rev Genet 2005; 6: 782–792.
8.
Gowrishankar B, Przybycin CG, Ma C, et al: A genomic algorithm for the molecular classification of common renal cortical neoplasms: development and validation. J Urol 2015; 193: 1479–1485.
9.
Maruschke M, Koczan D, Reuter D, et al: Putative biomarker genes for grading clear cell renal cell carcinoma. Urol Int 2011; 87: 205–217.
10.
Maruschke M, Reuter D, Koczan D, Hakenberg OW, Thiesen HJ: Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management. BJU Int 2011; 108(2 Pt 2):E29–E35.
11.
Thiesen HJ, Steinbeck F, Maruschke M, Koczan D, Ziems B, Hakenberg OW: Stratification of clear cell renal cell carcinoma (ccRCC) genomes by gene-directed copy number alteration (CNA) analysis. PLoS One 2017; 12: e0176659.
12.
Wang ET, Moyzis RK: Genetic evidence for ongoing balanced selection at human DNA repair genes ERCC8, FANCC, and RAD51C. Mutat Res 2007; 616: 165–174.
13.
Greenman CD, Bignell G, Butler A, et al: PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data. Biostatistics 2010; 11: 164–175.
14.
R Core Team (2013): R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. URL http://www.R-project.org/.
15.
Catalogue of Somatic Mutations in Cancer 2013. http://www.sanger.ac.uk/genetics/CGP/cosmic (cited January 26, 2013).
16.
Kanehisa M, Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000; 28: 27–30.
17.
Cifola I, Spinelli R, Beltrame L, et al: Genome-wide screening of copy number alterations and LOH events in renal cell carcinomas and integration with gene expression profile. Mol Cancer 2008; 7: 6.
18.
van den Berg A, Dijkhuizen T, Draaijers TG, et al: Analysis of multiple renal cell adenomas and carcinomas suggests allelic loss at 3p21 to be a prerequisite for malignant development. Genes Chromosomes Cancer 1997; 19: 228–232.
19.
Hagenkord JM, Gatalica Z, Jonasch E, Monzon FA: Clinical genomics of renal epithelial tumors. Cancer Genet 2011; 204: 285–297.
20.
Park RW, Kim TM, Kasif S, Park PJ: Identification of rare germline copy number variations over-represented in five human cancer types. Mol Cancer 2015; 14: 25.
21.
Thrash-Bingham CA, Greenberg RE, Howard S, et al: Comprehensive allelotyping of human renal cell carcinomas using microsatellite DNA probes. Proc Natl Acad Sci U S A 1995; 92: 2854–2858.
22.
Sato Y, Yoshizato T, Shiraishi Y, et al: Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 2013; 45: 860–867.
23.
Brugarolas J: Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol 2014; 32: 1968–1976.
24.
Testa JR, Cheung M, Pei J, et al: Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011; 43: 1022–1025.
25.
Peña-Llopis S, Christie A, Xie XJ, Brugarolas J: Cooperation and antagonism among cancer genes: the renal cancer paradigm. Cancer Res 2013; 73: 4173–4179.
26.
Dituri F, Mazzocca A, Giannelli G, Antonaci S: PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors. Clin Dev Immunol 2011; 2011: 947858.
27.
Mendoza MC, Er EE, Blenis J: The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 2011; 36: 320–328.
28.
Slomovitz BM, Coleman RL: The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 2012; 18: 5856–5864.
29.
Cancer Genome Atlas Research Network (346 collaborators): Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499: 43–49.
30.
Iacovelli R, Santoni M, Verzoni E, et al: Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data. Clin Genitourin Cancer 2015; 13: 137–141.
31.
Ortolani S, Ciccarese C, Cingarlini S, et al: Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives. Future Oncol 2015; 11: 1809–1828.
32.
Ghidini M, Petrelli F, Ghidini A, et al: Clinical development of mTor inhibitors for renal cancer. Expert Opin Investig Drugs 2017; 26: 1229–1237.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.